GCP
CATX icon

GSA Capital Partners’s Perspective Therapeutics CATX Stock Holding History

GSA Capital Partners’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
293,782
+256,465
+687% +$969K 0.06% 501
2026
Q1 		$156K Sell
37,317
-48,895
-57% -$207K 0.01% 1508
2025
Q4 		$237K Buy
+86,212
New +$246K 0.02% 1304
2015
Q3 		– Sell
-4,810
Closed -$71K – 1763
2015
Q2 		$71K Buy
4,810
+3,610
+301% +$58.5K ﹤0.01% 1885
2015
Q1 		$19K Buy
+1,200
New +$17.8K ﹤0.01% 2075

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

GSA Capital Partners's CATX Position: Q2 2026 in Review

GSA Capital Partners increased its Perspective Therapeutics (CATX) stake by 687% in Q2 2026, buying an estimated $969K and bringing the position to 293,782 shares worth $1M. The position accounts for 0.06% of the portfolio, ranked #501.

GSA Capital Partners first reported a position in CATX in Q1 2015 and has held it in 5 quarters since. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • GSA Capital Partners held 293,782 shares of Perspective Therapeutics worth $1M as of Q2 2026.
  • GSA Capital Partners bought 256,465 Perspective Therapeutics shares in Q2 2026, an estimated $969K.
  • Perspective Therapeutics made up 0.06% of GSA Capital Partners's portfolio in Q2 2026, its #501 holding.
  • GSA Capital Partners first reported a position in Perspective Therapeutics in Q1 2015 and has held it in 5 quarters since.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.